Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset?
Hims & Hers Health (NYSE:HIMS) shares fell over 6% after it reported Q2 revenue up 38% to $753.2M and subscribers up 19% to 2.89M. Monthly revenue per average subscriber rose 21% to $92. Full-year revenue guidance was raised to $3.1B-$3.3B. Net loss was $86.3M (37c/share) vs profit a year earlier, with gross margin down to 64% from 76%.
How this was made
The 30-second read
Why it matters
Traders must reassess the durability of growth economics after the branded pivot, because the quarter combined strong revenue/subscriber growth with a large earnings miss and lower gross margin.
Market read
A guidance raise alongside margin and earnings deterioration sets up a near-term valuation debate for Hims’ GLP-1 branded growth trajectory.
What to watch
The article notes metric composition effects (Eucalyptus and one-time purchases) and that retention for newer branded cohorts is tracking in line, which could soften the margin-reset narrative if confirmed in subsequent quarters.
Background
Hims shifted its weight-loss strategy toward branded GLP-1 via a Novo Nordisk agreement and reduced broad compounded GLP-1 advertising in March.
Ticker impact
Hims raised full-year revenue guidance to $3.1B-$3.3B after reporting a net loss and a sharp gross margin drop to 64%.
Near-term volatility likely as traders weigh higher top-line against weaker gross margin and net loss.
The article pairs a guidance raise with worse earnings metrics (net loss vs profit, gross margin down from 76% to 64%), which typically pressures valuation multiples even when growth accelerates.
Market effects
Telehealth and GLP-1-adjacent subscription models face scrutiny on whether branded drug economics can replace compounded margins.
Primarily US-focused read-through via domestic revenue growth and subscriber adds.
Limited direct global impact mentioned, though international expansion is framed as part of the longer-term margin story.
Counterpoint
The branded GLP-1 transition may be temporarily margin-dilutive, but retention and domestic growth resilience suggest the revenue engine is intact.
Key entities
- companyHims & Hers Health, Inc.
Telehealth provider reporting rapid subscriber and revenue growth, raised FY revenue outlook, but delivered net loss and gross margin compression after its branded GLP-1 pivot.
- companyNovo Nordisk
Partner referenced for the branded weight-loss assortment agreement that supported the product model transition.
- companyEucalyptus
Subscriber base acquisition mentioned as contributing to net additions during the branded transition period.
